|
|
 |
Search published articles |
 |
|
Showing 3 results for Zorriehzahra
Mohammad Jalil Zorriehzahra, Maryam Dadar, Mina Ziarati, Masoud Seidgar, Fatemeh Hassantabar, Samira Rashidi Monfared, Mohaddes Ghasemi, Laleh Yazdanpanah Goharrizi, Monireh Faeed, Roxana Fallahi, Volume 2, Issue 1 (Spring 2020)
Abstract
Background and Aim: In late 2019, a new viral disease, called COVID-19, caused by SARS-CoV-2, began in China and soon became a pandemic. COVID-19 is a threat to human health and causes human and financial losses in societies. Therefore, researchers are working to identify and control it more quickly. This review provides the newest information on COVID-19.
Methods: The data in this review are extracted from the latest articles related to COVID-19 and include the origin of the virus and its transmission routes, eco-epidemiology, incubation period and the symptoms of the disease, and perspectives on its control and prevention.
Results: SARS-CoV-2 is known as a zoonotic agent with high gene mutation. COVID-19 symptoms are numerous and the most important mode of transmission is respiratory droplets. Therefore, the patient's history, diagnosis of general symptoms, laboratory findings, chest imaging, serological and molecular diagnosis, can be effective in identifying patients as soon as possible, controlling and preventing.
Conclusion: There is still no effective drug or vaccine to prevent the disease and investigation in this field is ongoing. The only way to prevent and control the disease is adherence to the health protocols.
Mahtab Moshref, Mozhgan Taghdisi, Seyed Mohammad Jazayeri, Neda Soleimani, Seyed Mohammad Jalil Zorriehzahra, Mina Ziarati, Laleh Yazdanpanah Goharrizi, Maedeh Talebi, Seyedeh Sajedeh Mousavi, Volume 3, Issue 4 (COVID-19 Supplement 2021)
Abstract
In order to prevent the further spread of the COVID-19 pandemic caused by SARS-CoV-2, there is a need to develop rapid and reliable diagnostic tests. Given that there is currently no effective antiviral drug for COVID-19, the most important current strategy is to identify patients as soon as possible. Therefore, scientists and researchers are conducting experiments for rapid detection of asymptomatic carriers of COVID-19, to control and prevention of this epidemic.
Although some aspects of the structural and molecular characteristics of SARS-CoV-2 are unknown, various strategies for the correct diagnosis of COVID-19 have been proposed by research laboratories and medical companies, some of which are presented in the present study. According to studies, rapid antigen and antibody tests, immunoenzymatic serological tests, and RT‑PCR-based molecular tests are the most widely used and valid diagnostic methods worldwide. In addition to these common methods, other methods include; techniques based on nucleic acid isothermal amplification, CRISPR/Cas based methods, new generation sequencing (NGS) techniques and biosensors are used in research fields to identify SARS-CoV-2.
In the present study, the recent technologies and techniques of various research institutes, as well as devices and commercial kits produced by companies for the diagnosis of COVID-19 are presented, so that familiarity with these efficient diagnostic methods is an important step in advancing scientific goals.
Fateme Afshar, Morteza Mahdavi, Mehrdad Memarian, Mohammad Jalil Zorriehzahra, Seyed Davood Hosseini, Volume 6, Issue 4 (Winter 2025)
Abstract
Background and Aim: The widespread and persistent COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), remains a serious global health threat and continues to place a heavy burden on humanity. Currently, several intramuscular vaccines have been successfully developed, and mass vaccination programs have progressed in many countries. There is growing evidence supporting the use of recombinant probiotics, particularly lactic acid bacteria (LAB), as vaccine carriers. Given the crucial role of the SARS-CoV-2 spike (S) glycoprotein in viral attachment, entry, and induction of neutralizing antibodies, the S protein has been widely targeted for vaccine development. This study aimed to clone and express the S2 subunit gene of the spike protein in Lactococcus lactis.
Methods: In this study, the S2 gene, which had been previously amplified and cloned into the pWPI plasmid, was used. The gene was amplified by PCR and subsequently isolated and cloned into the pJET-1.2/blunt plasmid as an intermediate step, then transferred to E. coli DH5α for improved preservation. The S2 gene was then excised from pJET-1.2/blunt, cloned into the pNZ8149 plasmid, and transferred to Lactococcus lactis NZ39000 for gene amplification and expression.
Results: The results demonstrated that the S2 gene (1432 bp) was successfully amplified, isolated, and cloned into the pNZ8149 plasmid. Following its transfer to L. lactis NZ39000, the S2 protein was expressed and detected as a 51 kDa band on SDS-PAGE.
Conclusion: The findings suggest that transferring pathogenic viral genes into beneficial gut bacteria (LAB) may provide a promising strategy for developing oral vaccine candidates.
|
|